# Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

> **NCT00379613** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 45 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** sugammadex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00379613
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-07
- **Primary completion:** 2004-07-14
- **Final completion:** 2004-07-14
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379613, "Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00379613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*